|
|
||||||||
Animal: RNA Viruses |
Division of Retrovirology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK1
School of Biological Sciences, University of Surrey, Guildford, Surrey GU2 7XH, UK2
Division of Virology, University College of London Medical School, Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK3
School of Animal and Microbial Sciences, University of Reading, Whiteknights, PO Box 228, Reading, Berks RG6 2AJ, UK4
Author for correspondence: Simon Jeffs. Fax +44 1707 649865. e-mail sjeffs{at}nibsc.ac.uk
Removal of the V1V3 loops from IIIB gp120 results in a protein, PR12, with altered immunogenicity compared to the full-length protein. Polyclonal immune sera raised in rats using PR12 as immunogen recognizes envelope glycoproteins of clades A, B, C, E, F and G and can neutralize chimeric human immunodeficiency virus type 1 (HIV-1) HXB2 viruses expressing envelopes from primary HIV-1 clades B, C, E and F. These data suggest that the immune response to PR12 is directed toward conserved epitopes expressed by viral glycoproteins of diverse genotypes. Five monoclonal antibodies (mAb) derived from PR12-immunized rats were unable to neutralize virus infectivity; hence the epitopes responsible for the induction of this cross-clade neutralizing activity remain to be elucidated. However, PR12 immune sera were able to compete with the human neutralizing mAb 2G12 for gp120 binding, implying that this epitope may be immunogenic when expressed in the context of this truncated protein.
This article has been cited by other articles:
![]() |
M. Montero, N. E. van Houten, X. Wang, and J. K. Scott The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design Microbiol. Mol. Biol. Rev., March 1, 2008; 72(1): 54 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Gorny, C. Williams, B. Volsky, K. Revesz, X.-H. Wang, S. Burda, T. Kimura, F. A. J. Konings, A. Nadas, C. A. Anyangwe, et al. Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1 J. Virol., July 15, 2006; 80(14): 6865 - 6872. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Poon, J. F. Hsu, V. Gudeman, I. S. Y. Chen, and K. Grovit-Ferbas Formaldehyde-Treated, Heat-Inactivated Virions with Increased Human Immunodeficiency Virus Type 1 Env Can Be Used To Induce High-Titer Neutralizing Antibody Responses J. Virol., August 15, 2005; 79(16): 10210 - 10217. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Poon, J. T. Safrit, H. McClure, C. Kitchen, J. F. Hsu, V. Gudeman, C. Petropoulos, T. Wrin, I. S. Y. Chen, and K. Grovit-Ferbas Induction of Humoral Immune Responses following Vaccination with Envelope-Containing, Formaldehyde-Treated, Thermally Inactivated Human Immunodeficiency Virus Type 1 J. Virol., April 15, 2005; 79(8): 4927 - 4935. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Trujillo, N. M. Kumpula-McWhirter, K. J. Hotzel, M. Gonzalez, and W. P. Cheevers Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody Responses J. Virol., September 1, 2004; 78(17): 9190 - 9202. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-Y. Zhang, X. Xiao, I. A. Sidorov, V. Choudhry, F. Cham, P. F. Zhang, P. Bouma, M. Zwick, A. Choudhary, D. C. Montefiori, et al. Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody J. Virol., September 1, 2004; 78(17): 9233 - 9242. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lorin, L. Mollet, F. Delebecque, C. Combredet, B. Hurtrel, P. Charneau, M. Brahic, and F. Tangy A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV J. Virol., January 1, 2004; 78(1): 146 - 157. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |